Monograph
J07CA02 - Diphtheria-Pertussis-Poliomyelitis-Tetanus |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the diphtheria-pertussis-poliomyelitis-tetanus vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Diphtheria Toxoid, Tetanus Toxoid, Pertussis Toxoid and inactivated poliovirus (type 1,2 and 3) (DTP-IPV)
Therapeutic characteristics
The DTP-IPV vaccine is indicated for active immunization against diphtheria, tetanus, pertussis and poliomyelitis both for primary immunization and for following booster doses. It is administered by intramuscular injections.
Metabolism and pharmacokinetics
The DTP-IPV vaccine is not metabolized by the cytochrome P450 system.
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
| * | Summary of Product Characteristics | |
| 2. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Tetravac. (Last edition: 30.06 2014).
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia© NAPOS 2024